Tag: Cancer: Prostate
No Difference in Toxicity for 6-, 2-Fraction HDR in Prostate Cancer
Urinary, sexual toxicity similar with 6-, 2-fraction high-dose-rate brachytherapy regimen
Re-Analysis Shows Screening Reduces Prostate CA Mortality
In re-analysis, screening conferred 7 to 9 percent reduction in risk in ERSPC and PLCO trials
Androgen-Deprivation Therapy May Carry Cardiovascular Risks
Findings in men with clinically localized prostate cancer initially under active surveillance
Osteoporosis Meds Up BMD in Nonmetastatic Prostate Cancer
Review shows improved bone mineral density in men receiving androgen deprivation therapy
Infection Is Most Common Complication of Prostate Biopsy
Fluoroquinolone-resistant E. coli plays prominent role in infection; rates range from 0.1 to 7.0 percent
Vascular Targeted Photodynamic Tx Aids Low-Risk Prostate Cancer
Achieves an 82 percent rate of absent clinically significant cancer in treated lobes
Study Supports Observation Only for Most Low-Risk Prostate CA
20-year study found little difference in mortality rates, more complications with surgery
Tall, Obese Men at Higher Risk of Aggressive Prostate Cancer
Study found taller, heavier males were more likely to develop prostate cancer, die from it
Decisional Regret Doesn’t Differ by Treatment in Prostate Cancer
Only African-American race was associated with greater regret across time
Germline Mutations Up in Men With Prostate CA, One Other CA
However, most of these men do not meet current clinical criteria for germline testing
